ArticleCritical care science2025
Risk factors, impact on outcomes, and molecular epidemiology of infections caused by carbapenem-resistant Enterobacterales in intensive care patients: a multicenter matched case-control study in Brazil.
Article in Critical care science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- To: Risk factors, impact on outcomes, and molecular epidemiology of infections caused by carbapenem-resistant Enterobacterales in intensive care patients: a multicenter matched case-control study in Brazil.Critical care science · 2025Article
- Standardized pre-bronchoscopy mechanical power and KPC resistance as predictors of mortality in ventilated ICU patients: a retrospective cohort study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate risk factors, molecular profiles, and hospital mortality of carbapenem-resistant Enterobacterales (CRE) infections in intensive care unit patients.
methodsIn this retrospective, multicenter cohort study, intensive care unit admissions from 52 intensive care units between January 2019 and December 2020 were analyzed in a nested case-control design. Patients with carbapenem-resistant Enterobacterales infections were propensity score-matched 1:1 to those with carbapenem-susceptible Enterobacterales infections. Hierarchical conditional logistic regression identified risk factors for carbapenem-resistant Enterobacterales, and multivariable logistic regression assessed the association of carbapenem-resistant Enterobacterales with 60-day in-hospital mortality. Molecular genotyping was also conducted.
resultsMatching resulted in 250 carbapenem-resistant Enterobacterales patients and 250 carbapenem-susceptible Enterobacterales patients. Sepsis was more common in the carbapenem-resistant Enterobacterales group (58% versus 35%; p < 0.001). Risk factors for carbapenem-resistant Enterobacterales included major premorbid assistance requirements (OR 1.72, 95%CI 0.99 - 3.01; p = 0.06) and intensive care unit readmission (OR 1.87, 95%CI 1.00 - 3.49; p = 0.05), although with weak associations. Acute COVID-19 (OR 3.55, 95%CI 1.96 - 6.45; p < 0.001) also increased the odds of resistance. Carbapenem-resistant Enterobacterales infection was associated with twice the likelihood of 60-day mortality after adjusting for covariates (OR 1.95, 95%CI 1.26 - 3.02; p < 0.001). The predominant bacteria and carbapenemase resistance genes included Klebsiella pneumoniae (79%), Klebsiella pneumoniae carbapenemase (73%), New Delhi metallo-beta-lactamase (13%), and xacillinase-48 (9%).
conclusionCarbapenem-resistant Enterobacterales-related infections in intensive care unit patients were associated with major premorbid dependence, intensive care unit readmission, and acute COVID-19. In addition, carbapenem-resistant Enterobacterales infections were independently associated with poorer hospital outcomes. This study also characterized the resistance profile of Enterobacterales in Brazilian intensive care units, which are dominated by K. pneumoniae with high rates of carbapenemase and increased rates of New Delhi metallo-beta-lactamase, in comparison with previous reports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.